NCT06611514View on ClinicalTrials.gov

Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

95

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Women With Breast Cancer

Interventions

DRUG

Prasterone (DHEA)

Prasterone 6.5 mg vaginal tablets

Trial Locations (1)

20141

European Institute of Oncology, Milan

All Listed Sponsors

lead

European Institute of Oncology

OTHER